Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab for preservation of pancreatic β-cell function in newly diagnosed type 1 diabetes (FABULINUS)
2022-500531-36-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Frexalimab + insulin with Placebo + insulin (2 arms). Planned start Dec 2023; status: authorised.
02
Drugs
frexalimab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2022-500531-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500531-36-00.